• The FDA will meet on Thursday, December 17 to review Moderna's vaccine application. The green light is expected to be given as early as Friday, December 18 and the launch of the vaccination could start as early as Monday, December 21, Reuters reports.
  • The EU is expected to license Pfizer and BioNTech's vaccine on December 23.
  • Google faced another major malfunction in its Gmail email system.
  • In cannabis, Tilray and Aphria will merge.
  • Twitter will close its Periscope application by March.
  • Moody's confirms AstraZeneca's A3 credit rating, but changes the outlook from positive to stable.
  • MSCI removes seven Chinese companies from its indexes: Semiconductor Manufacturing International, CRCC, Dawning Info, Hangzhou Hikvis, China Communications, China Rail and China Railways.
  • Credit Suisse will cut about 10 percent of its asset management staff, out of about 1,100 employees, the head of the division told Bloomberg.
  • Palo Alto Networks is finalizing the acquisition of Expanse for the equivalent of $800 million.
  • Air Canada launches a capital increase of CAD 850 M.
  • Gilead and Galapagos will not submit Jyseleca (filgotinib) to the FDA in rheumatoid arthritis.
  • Novartis achieves "therapeutic breakthrough" status for iptacopan.
  • The IPO price for Wish shares was set at the high end of the range at USD 24.
  • The giant hacking of several US agencies and companies is said to have originated from a flaw in SolarWinds Corporation software.
  • Bone Therapeutics raises $12 million by private placement.
  • Semiconductor Manufacturing International wins over rumors of a class action lawsuit in the U.S. over a misrepresentation of its financial performance.